• Ziopharm Oncology Inc., of New York, said an independent data monitoring committee unanimously recommended continuation of its international, randomized, double-blind, placebo-controlled Phase III trial of palifosfamide (Zymafos, or ZIO-201), dubbed PICASSO 3, in front-line metastatic soft tissue sarcoma – the third such review and recommendation by the committee.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter